Compare · Head-to-head
Semaglutide vs Tesamorelin.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Tesamorelin, then use the table to confirm fit.
Tesamorelin is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | Semaglutide | Tesamorelin |
|---|---|---|
| Primary fit | fat loss & metabolism research where you want a clear starting point | fat loss & metabolism and gh axis optimization comparisons |
| Evidence | Tier A | Tier A |
| Risk | medium | low |
| Experience level | intermediate | advanced |
| Budget tier | premium | premium |
| Administration route | subcutaneous, oral | subcutaneous |
02 · Use case & timing
| Decision factor | Semaglutide | Tesamorelin |
|---|---|---|
| Goal fit | Fat Loss & Metabolism | Fat Loss & Metabolism, GH Axis Optimization |
| What users compare it for | Clinically meaningful appetite reduction, HbA1c improvement, and substantial body-weight reduction in approved-use populations. | Visceral fat reduction in HIV lipodystrophy (evidence-backed). General weight loss claims are limited. |
| Onset timeline | Glucose effects emerge over the first weeks; weight-loss effects build across 3 to 12 months. | Clinical endpoints assessed at 26 weeks in pivotal studies. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Semaglutide | Tesamorelin |
|---|---|---|
| Adverse effects | Common GI adverse effects include nausea, vomiting, diarrhea, and constipation. Gallbladder and pancreatitis concerns exist, and thyroid C-cell tumor warning remains part of class labeling. | Increased neoplasm risk, elevated IGF-1, fluid retention, glucose intolerance/diabetes, hypersensitivity. |
| Contraindications | Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history, severe gastroparesis, pregnancy, and concurrent insulin/sulfonylureas. | Active malignancy, pregnancy, pituitary gland disorders (per label). |
| Interaction notes | Additive hypoglycemia risk with insulin or sulfonylureas. Delayed gastric emptying can alter absorption timing for oral drugs. | CYP450-metabolized drugs; glucocorticoid replacement requirements may be affected. |
| Regulatory status | Prescription-approved | Prescription-approved |
| FDA flag | FDA compounding caution | No current flag noted |
| WADA status | Not listed | WADA S2 |
04 · Age & monitoring
| Decision factor | Semaglutide | Tesamorelin |
|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54, 55-64, 65+ | No age guidance yet |
| Life-stage note | Strongest fit for adults where weight, glucose control, and cardiometabolic risk are part of the decision. | Not yet documented |
| Monitoring burden | medium | Not specified |
| Follow-up cadence | Early tolerance review in the first weeks, then metabolic follow-up every few months. | Not yet documented |
05 · Cost & sourcing
| Decision factor | Semaglutide | Tesamorelin |
|---|---|---|
| Typical cycle cost | $120.00 | $600.00 |
| Estimated monthly cost | $120.00 | $600.00 |
| Cost confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | Semaglutide | Tesamorelin |
|---|---|---|
| Tracked vendor listings | 1 listing | 3 listings |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | Tracked product pages exist, but naming differences mean the listing needs an extra read before purchase. |
| Stack-friendly? | Usually stack-friendly | Better as a standalone decision |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.